Literature DB >> 31318185

Patches: Established and Emerging Transdermal Treatments in Psychiatry.

Leslie Citrome1,2, Courtney M Zeni3, Christoph U Correll4,5.   

Abstract

Transdermal delivery is an alternative to oral routes of drug administration and has made considerable contributions to the treatment of various medical diseases. With the advent of new transdermal delivery technologies, higher numbers of medications are being approved for use as transdermal formulations. This route of administration has several innate advantages that have the potential to benefit various patient populations, including those with central nervous system disorders. The current review briefly outlines the history of transdermal medications, discusses the advantages and disadvantages of transdermal formulations, and examines the challenges and opportunities present for the use of transdermal treatments in psychiatry. Patients with psychiatric illnesses have many unmet needs that may be filled through the benefits gained from transdermal treatments, such as reduced dosing frequency, effective control of plasma medication concentrations, improved tolerability, ability to check compliance visually, and avoidance of first-pass hepatic metabolism. Established transdermal treatments for various psychiatric diseases are discussed followed by an introduction to therapies that are being developed as the first patch formulations for the treatment of schizophrenia. Hypothetical schizophrenia patient profiles are also outlined to aid providers in considering how transdermal treatments for this disease may fill unmet needs for specific patients. The evidence demonstrating the potential benefits of transdermal treatments in psychiatry presented in the current review should both encourage health care providers to consider how patients may benefit from transdermal alternatives and promote future innovation in the area of transdermal drug delivery for psychiatric disorders. © Copyright 2019 Physicians Postgraduate Press, Inc.

Entities:  

Year:  2019        PMID: 31318185     DOI: 10.4088/JCP.18nr12554

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  5 in total

1.  Prediction of Corresponding Dose of Transdermal Blonanserin to Oral Dose Based on Dopamine D2 Receptor Occupancy: Unique Characteristics of Blonanserin Transdermal Patch.

Authors:  Yoshiko Tomita; Takeshi Takagaki; Atsushi Kitamura; Erika Wada; Hironori Nishibe; Amane Tateno; Yoshiro Okubo
Journal:  J Clin Psychopharmacol       Date:  2022-04-05       Impact factor: 3.118

Review 2.  Transdermal Asenapine in Schizophrenia: A Systematic Review.

Authors:  Brennan Carrithers; Rif S El-Mallakh
Journal:  Patient Prefer Adherence       Date:  2020-08-25       Impact factor: 2.711

3.  Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).

Authors:  Katsumi Suzuki; Mariacristina Castelli; Marina Komaroff; Brittney Starling; Takaaki Terahara; Leslie Citrome
Journal:  J Clin Psychopharmacol       Date:  2021 May-Jun 01       Impact factor: 3.118

4.  Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study.

Authors:  Andrew J Cutler; Katsumi Suzuki; Brittney Starling; Kanan Balakrishnan; Marina Komaroff; Mariacristina Castelli; Suzanne Meeves; Ann C Childress
Journal:  J Child Adolesc Psychopharmacol       Date:  2022-01-11       Impact factor: 2.576

5.  Striatal Dopamine D2 Receptor Occupancy Induced by Daily Application of Blonanserin Transdermal Patches: Phase II Study in Japanese Patients With Schizophrenia.

Authors:  Hironori Nishibe; Amane Tateno; Takeshi Sakayori; Masahiro Yamamoto; WooChan Kim; Hiroyoshi Kakuyama; Yoshiro Okubo
Journal:  Int J Neuropsychopharmacol       Date:  2021-02-15       Impact factor: 5.176

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.